Skip to main content
. 2022 Mar 15;12:4398. doi: 10.1038/s41598-022-08449-w

Figure 3.

Figure 3

(A) OS of EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy by the baseline status of brain metastasis (B) Cumulative incidence of systemic progression without death (red) and CNS progression alone without death (black) between EGFR-TKI plus bevacizumab and EGFR-TKI monotherapy groups in patients with baseline brain metastasis. bev bevacizumab, BM brain metastasis, TKI tyrosin kinase inhibitor.